FierceBiotech
@FierceBiotech
The dominant B2B news brand for biotech. Delivering news, revealing insights straight to your inbox.
加入 December 2008
615 正在关注 102.7K 粉丝
Genentech is paying Alector $100 million upfront for exclusive rights to a preclinical drug candidate that targets a driver of neurodegeneration in Parkinson’s disease.
